Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, October 27, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that they
/PRNewswire/ DelveInsight s Cystic Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, cystic fibrosis.
The overall cystic fibrosis market is expected to surge due to the increasing prevalence of the disease and expected launch of emerging therapies including Ensifentrine, VX-121/TEZ/ VX561, and
Pratteln, Switzerland, October 3, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the Company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA)